| abstract |
Treatment of B cell malignancies with immunomodulatory antibodies, in particular anti-B7, anti-CD23, or anti-CD40L antibodies and B cell depleted antibodies, in particular anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibodies Combination antibody therapy is provided for the following. Preferably, this combination therapy will comprise administration of anti-B7 and anti-CD20 antibodies. |